Monday, December 4, 2006 Panel Session Co-Morbid Pain
Neuropsychopharmacology (2006) 31, S1-S69 © 2006 Nature Publishing Group All rights reserved 0893-133X/06 www.neuropsychopharmacology.org S1 Monday, December 4, 2006 sented on the involvement of these neurotransmitter systems in re- sponses to sustained pain, a physical and emotional stressor, and their Panel Session dysregulation in chronic pain conditions. In addition, we will discuss Co-Morbid Pain and Addiction: Novel Treatments the psychophysical implications of inter-individual differences in DA D2 and µ-opioid receptor availability and in the capacity to activate these neurotransmitter systems. These will be discussed in the con- Clinically Significant Advances in Understanding Opiate text of the contribution of sex, gonadal steroids, common genetic Receptors polymorphisms and cognitive factors to these individual variations. Gavril W. Pasternak* Regarding the latter, we will discuss recent and new data on the ef- fects of expectation of relief on the function of these neurotransmit- Molecular Pharmacology, Memorial-Sloan Kettering, New York, tersystems and associated neuronal circuits and their contribution to NY, USA individual differences in placebo responding. Examination of these Opiates are widely used in the treatment of pain. Clinicians have long cognitively-modulated, resiliency mechanisms further provides a recognized the need to individualize therapy based upon the widely novel avenue for the development of treatment strategies and the un- varying responses of individual patients. However, the reasons for derstanding of treatment non response in various neuropsychiatric this have remained obscure. Most of the opiates used clinically are se- conditions. lective for mu, or morphine-preferring, receptors, raising the ques- tion why the disparities in response among patients can be so great.
[Show full text]